• Source : Press Release
  • Date : 2021-07-28
  • Event type : Marketed
  • Companies : Tosoh Corp.

Tosoh Launches an AIA-Series Reagent for TFPI2, a Novel Biomarker for Ovarian Cancer in Japan

Tokyo, Japan—Tosoh Corporation has begun marketing an enzyme immunoassay (EIA) reagent for measuring serum TFPI2 (Tissue Factor Pathway Inhibitor 2), a novel biomarker used as an aid in the diagnosis of ovarian cancer. This reagent was developed as an AIA-series reagent for Tosoh automated enzyme immunoassay AIA analyzers, and on sale in Japan under the name E-Test TOSOH® II (TFPI2) as from July 28, 2021.

Serum TFPI2 is known to show high levels for patients of ovarian cancer, especially of ovarian clear-cell carcinoma (CCC) but not of benign tumors such as endometriosis. Since CCC often exhibits resistance against standard chemotherapies, and gives low or normal levels of serum CA125, which is widely used as an ovarian cancer biomarker, TFPI2 can be used to discriminate patients with CCC before surgery and a higher sensitivity to detect CCC may be expected when used in combination with CA125.

The E-Test TOSOH II (TFPI2) was developed based on the results from collaborative study for novel diagnostic biomarkers for ovarian cancer conducted with Yokohama City University. The study was part of a project initiated by the Ministry of Education, Culture, Sports, Science and Technology of Japan to promote innovation through “Establishment of Research Center for Clinical Proteomics of Post-translational Modifications”.    

Looking ahead, Tosoh Corporation plans to continue expanding its lineup of valuable diagnostic products with the goal of contributing to medical and healthcare facilities.

Overview of the product

Product name


Approval number from Pharmaceuticals and Medical Devices Agency


Assay principle

One-step sandwich enzyme immunoassay (EIA)

Report time

Approx. 20 minutes

Sample amount and type

20 microliters of serum

Applicable analyzers

Tosoh’s AIA-2000, AIA-1800, AIA-900, AIA-600II, and AIA-360 models

Medical reimbursement points

190 points (contribution to ovarian cancer diagnoses)


Who We Are

Tosoh Corporation is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 12,000 people. It generated net sales of ¥732.9 billion (US$6.9 billion at the average rate of ¥106.1 to the US dollar) in fiscal 2021, ended March 31, 2021.

What We Do

Tosoh is one of the largest chlor-alkali manufacturers in Asia. The company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh’s petrochemical operations supply ethylene, polyethylene, and functional polymers, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases. In addition, Tosoh demonstrates its commitment to a sustainable future in part by manufacturing a variety of eco-products.

Stock Exchange Ticker Symbol: 4042


This document may contain forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. Forward-looking statements are identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the results expressed in forward-looking statements.